Medicine and HealthNature Medicine
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial
J. Cortés, S. A. Hurvitz, et al.
Discover the groundbreaking results of the DESTINY-Breast03 trial, where trastuzumab deruxtecan (T-DXd) demonstrated remarkable efficacy over trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer treatment. With a follow-up of 41 months, T-DXd achieved a median overall survival of 52.6 months, changing the landscape of breast cancer therapy. This impactful research was conducted by an esteemed group of authors.
Related Publications
Explore these studies to deepen your understanding
Adjacent work that informs or extends this paper's methodology and findings.
Medicine and Health
Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial
K. Shitara, Y. Bang, et al.
Medicine and Health
Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial
N. Harbeck, E. Ciruelos, et al.
Medicine and Health
Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial
D. H. Ryan, I. Lingvay, et al.
Medicine and Health
Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial
D. H. Ryan, I. Lingvay, et al.
